Treatment of Philadelphia leukemia in severe combined immunodeficient mice by combination of cyclophosphamide and bcr/abl antisense oligodeoxynucleotides

Journal of the National Cancer Institute
T SkorskiB Calabretta

Abstract

Philadelphia cells are human chronic myelogenous leukemia (CML) cells that contain the BCR/ABL oncogene (a fusion of the BCR and ABL genes). Selective eradication of these cells in vitro can be achieved by combined treatment with antisense phosphorothioate oligodeoxynucleotides ([S]ODNs) specifically targeted to this oncogene (bcr/abl [S]ODNs) and a suboptimal (for use as a single agent) dose of mafosfamide (the in vitro active form of cyclophosphamide). We evaluated the ability of bcr/abl antisense [S]ODNs, alone or subsequent to treatment with a single injection of cyclophosphamide, to suppress the leukemic process induced in severe combined immunodeficient (SCID) mice by Philadelphia cells (i.e., primary CML-blast crisis [CML-BC] cells). In addition, we studied potential mechanisms that might explain the efficacy of the bcr/abl antisense [S]ODN-mafosfamide combination against Philadelphia cells in vitro. The effects of treating leukemic mice with cyclophosphamide (25 mg/kg body weight; 25% of the dose required to eradicate evidence of leukemia in SCID mice) and/or bcr/abl antisense [S]ODNs were assessed by analysis of survival, by examination of bone marrow for the presence of leukemia cells (using a colony formation assay o...Continue Reading

References

Dec 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·M Z RatajczakA M Gewirtz
Sep 18, 1992·Cell·C L SawyersO N Witte
Sep 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·S AgrawalJ Y Tang
Jul 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·E FeinsteinE Canaani
Sep 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·L A YakubovV V Vlassov
Sep 1, 1981·International Journal of Radiation Biology and Related Studies in Physics, Chemistry, and Medicine·S Chandra, S Stefani
Oct 22, 1993·Cell·D M HockenberyS J Korsmeyer
Apr 1, 1995·The Journal of Clinical Investigation·C BeltingerA M Gewirtz
Jun 6, 1995·Proceedings of the National Academy of Sciences of the United States of America·I Sánchez-García, G Grütz
Nov 4, 1994·Science·S W LoweT Jacks
May 10, 1994·Proceedings of the National Academy of Sciences of the United States of America·T SkorskiB Calabretta
Jan 1, 1993·Antisense Research and Development·R M Bennett

❮ Previous
Next ❯

Citations

Sep 25, 1999·Journal of Cellular Physiology·U GalderisiA Giordano
May 12, 2000·Biochimica Et Biophysica Acta·N Agarwal, A M Gewirtz
May 30, 2001·Experimental Hematology·B N JahagirdarC M Verfaillie
Oct 30, 1998·Critical Reviews in Oncology/hematology·M ClynesK Scanlon
Oct 18, 2003·Seminars in Cancer Biology·Christine Damm-WelkArndt Borkhardt
Aug 28, 2002·Reviews in Clinical and Experimental Hematology·Stefan FaderlHagop M Kantarjian
Jan 15, 1997·Journal of the National Cancer Institute·R Narayanan
Nov 14, 1997·Proceedings of the National Academy of Sciences of the United States of America·G TortoraF Ciardiello
Mar 28, 2012·Leukemia & Lymphoma·Rathi N PillaiVarsha Gandhi
Feb 17, 2001·The Journal of Investigative Dermatology·L AurelianJ W Burnett
May 4, 2002·Best Practice & Research. Clinical Haematology·Jerald P Radich
Mar 21, 2002·Expert Opinion on Therapeutic Targets·T KindlerT Fischer
Aug 30, 2000·Oncogene·M Nieborowska-SkorskaT Skorski
Sep 24, 2002·The Journal of Immunology : Official Journal of the American Association of Immunologists·Satoko OhnoKohzoh Imai
Apr 9, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Barbara BucciAldo Vecchione
Sep 28, 2000·Cancer Treatment Reviews·W PawlakC Szczylik

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Antisense Oligonucleotides: ND

This feed focuses on antisense oligonucleotide therapies such as Inotersen, Nusinursen, and Patisiran, in neurodegenerative diseases including amyotrophic lateral sclerosis.